Brucke Financial Inc. Trims Position in Sanofi $SNY

Brucke Financial Inc. lessened its stake in Sanofi (NASDAQ:SNY) by 6.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,326 shares of the company’s stock after selling 566 shares during the period. Brucke Financial Inc.’s holdings in Sanofi were worth $402,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD increased its stake in Sanofi by 1.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,036,878 shares of the company’s stock worth $612,106,000 after buying an additional 193,196 shares during the period. Federated Hermes Inc. increased its stake in Sanofi by 58.5% in the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock worth $218,933,000 after buying an additional 1,456,269 shares during the period. Envestnet Asset Management Inc. increased its stake in Sanofi by 6.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company’s stock worth $181,764,000 after buying an additional 211,641 shares during the period. Raymond James Financial Inc. increased its stake in Sanofi by 15.1% in the 1st quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock worth $179,914,000 after buying an additional 425,597 shares during the period. Finally, Nuveen LLC purchased a new position in Sanofi during the 1st quarter valued at about $177,831,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $56.00 to $58.00 in a research report on Monday, September 8th. Barclays reissued an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Finally, JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Sanofi has a consensus rating of “Buy” and an average price target of $62.67.

Sanofi Stock Down 1.5%

NASDAQ:SNY opened at $48.09 on Friday. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The stock has a market capitalization of $118.09 billion, a P/E ratio of 11.56, a P/E/G ratio of 1.19 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The company’s 50-day simple moving average is $48.27 and its 200-day simple moving average is $49.82.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter in the prior year, the business posted $1.73 earnings per share. The firm’s quarterly revenue was down 7.0% on a year-over-year basis. On average, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.